Dr. Konstantin Schimert (CEO) and Dr. Gundel Hager (CSO) have retired from their positions to pursue other opportunities. AURIGON is full of gratitude for the outstanding contributions of Dr. Hager and Dr. Schimert to the development of the company.
AURIGON is very pleased to win the experienced Pharma manager Dr. István Gacsályi as Managing Director for both Aurigon GmbH (Munich) and ATRC Aurigon Ltd. (Dunakeszi/Budapest). Dr. Gacsályi is looking back on an extraordinary career within Les Laboratories Servier and EGIS Pharmaceuticals. Among his different managerial positions, being an International Project Leader and Head of Experimental Pharmacology are worth to mention. Referring to his new engagement Dr. Gacsályi claimed: “The future is the CRO-type drug development. CRO organizations are able to react faster and more flexible to market challenges than Big Pharmas. The real advantage of CRO’s like AURIGON is that they can provide innovative solutions for research partners. That’s why I joined AURIGON.” One of Dr. Gacsályi’s major goals for the near future is to strengthen AURIGON’s position as one of Europe’s leading service providers for research projects with Göttingen Minipigs.
AURIGON is a preclinical CRO with offices in Munich and GLP-certified laboratories in Hungary. It possesses a spacious site for small and large animal testing (rodents, rabbits, dogs, minipig...) including in vitro laboratories close to the city borders of Budapest. Furthermore AURIGON maintains a well-equipped bioanalytical department in Budapest.
The very heart of the company is the experienced and motivated staff, having up to 30 years of individual expertise. The staff is the excellent engine that enabled AURIGON to create a proven track record of 5600+ studies, performed with a variety of test item classes, such as NCE, NBE, vaccines or oligonucleotides.